Full Press Release Details
Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development.
ZYME
Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development
Key Takeaway: Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers